GlassScriptPhysician profile
Luis G Alvarez
NPI 1417951922
$3,361.01
in general payments reported to CMS, 2019-2025
26 companies · $540 in 2025
The $540 reported for 2025 was less than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
See the full distribution for Clinical Cardiac Electrophysiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $547 · 2020: $237 · 2021: $307 · 2022: $238 · 2023: $873 · 2024: $619 · 2025: $540.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,032.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,032.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $689.77 | 2019-2025 | Watchman Flx, Watchman Access System |
| Janssen Pharmaceuticals, INC | $570.51 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $258.29 | 2020-2025 | Breztri, Farxiga |
| E.R. Squibb & Sons, L.L.C. | $242.47 | 2023-2025 | Camzyos |
| Pfizer INC. | $234.53 | 2019-2025 | |
| Amgen INC. | $156.44 | 2019-2025 | Repatha, Repatha |
| Actelion Pharmaceuticals US, INC. | $150.00 | 2023 | Uptravi, Opsumit |
| Aurinia Pharma U.S., INC. | $118.87 | 2024 | Lupkynis |
| Abbott Laboratories | $117.35 | 2019-2022 | |
| Cvrx, INC. | $100.01 | 2024-2025 | Barostim Neo System |
| Novartis Pharmaceuticals Corporation | $94.26 | 2019-2025 | |
| Amarin Pharma, INC. | $87.42 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $84.91 | 2021-2024 | Verquvo |
| Astellas Pharma US INC | $74.83 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.39 | 2019-2023 | Jardiance |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bardy Diagnostics, INC. | $64.50 | 2019-2022 | |
| Novo Nordisk INC | $37.73 | 2022-2023 | Ozempic |
| Irhythm Technologies, INC. | $31.62 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $30.74 | 2019-2023 | Lifevest |
| Regeneron Healthcare Solutions, INC. | $29.15 | 2023 | Evkeeza |
| Lexicon Pharmaceuticals, INC. | $23.54 | 2023 | Inpefa |
| Impulse Dynamics (USA) INC. | $21.34 | 2022 | |
| Daiichi Sankyo INC. | $20.20 | 2023 | Injectafer |
| Otsuka America Pharmaceutical, INC. | $18.79 | 2025 | Jynarque |
| Baxter Healthcare | $18.42 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Glaxosmithkline, LLC. | $17.93 | 2025 | Arexvy, Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Alvarez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.